Drug Trial Radar · NCT03382574
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Last checked: Nov 19, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Mar 14, 2019
Primary completion
Oct 22, 2021
Study completion Oct 22, 2021
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Dec 26, 2017
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy. Denosumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Conditions
- Ovarian Carcinoma
Interventions
DenosumabBiological
Given SC
Salpingo-OophorectomyProcedure
Undergo risk-reducing salpingo-oophorectomy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ki67 Proliferation Index Fallopian Tube Fimbrial Epithelial CellsTime frame: Up to 12 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Dana-Farber Cancer Institute
Boston, Massachusetts
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York
NYP/Weill Cornell Medical Center
New York, New York
M D Anderson Cancer Center
Houston, Texas
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Chaim Sheba Medical Center
Tel HaShomer, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.